Latest News

Veda Giri, MD, Chief of Clinical Cancer Genetics and Co-Director of the Early Onset Cancer Program at Smilow Cancer Hospital and Yale Cancer Center, and Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology), have been named Fellows of the American Society of Clinical Oncology (FASCO).

Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.

The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.

Treatment outcomes were similar between Black and non-Black patients with triple-negative breast cancer who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy, according to phase I/II clinical trial results published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.

Cancer patients should be prescribed fitness classes and workouts to boost their survival, doctors say. Patients should try to do both muscle strengthening work and cardio exercises such as swimming - and even simple chores like gardening or carrying heavy shopping could improve health.

Lajos Pusztai, MD, DPhil speaks about the Cancer Relevance of Human Genes.

More human genes have been identified as driving cancer development than previously assumed. The study evaluated 12,767 human genes that interact, directly or indirectly, with certain core cancer genes, which are known to have a significant impact on the development of cancer.

Following an analysis of over 12,000 human genes, research from Yale Cancer Center indicates there is cancer-relevant importance in a much larger proportion of human genes than current cancer research models suggest.